Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Microsoft, Citrix, Weber Rise Premarket; Wynn Resorts Falls

Published 09/15/2021, 08:10 AM
Updated 09/15/2021, 08:11 AM
© Reuters.

© Reuters.

By Peter Nurse 

Investing.com -- Stocks in focus in premarket trade on Wednesday, September 15th. Please refresh for updates.

  • Microsoft (NASDAQ:MSFT) stock rose 1.2% after the software giant announced a $60 billion share buyback, with no expiration date, and a higher quarterly dividend.

  • Apple (NASDAQ:AAPL) stock rose 0.2%, with the world’s largest company rebounding after the previous session’s lukewarm response to the unveiling of its Phone 13 and a new iPad mini.

  • Chevron (NYSE:CVX) stock rose 0.5%, boosted by the rise in oil prices, even after JPMorgan (NYSE:JPM) downgraded the oil major, citing its ramp up in clean energy spending. The company said yesterday it will increase spending on alternative energy projects to $10 billion from $3 billion.

  • Wynn Resorts (NASDAQ:WYNN) stock fell 4.9%. MGM Resorts (NYSE:MGM) stock fell 1.5% and Las Vegas Sands (NYSE:LVS) stock dropped 4.5%, continuing Tuesday’s selloff after the government of Macau sought to increase regulatory scrutiny over casinos in the world’s largest gambling hub.

  • Weber (NYSE:WEBR) stock rose 2% after the maker of outdoor grills posted a strong first quarterly report since going public, with sales rising 19% from a year earlier.

  • Theravance Biopharma (NASDAQ:TBPH) stock fell 17% on the back of the biopharmaceutical company announcing its drug to treat hypotension did not meet its primary endpoint. It now intends to cut its workforce by around 75%.

  • Lucid Group (NASDAQ:LCID) stock rose 2.4% following Bank of America (NYSE:BAC) predicting a 50% gain, saying the newly floated electric vehicle company appears to be on a firm footing to become a real player in the growing market.

  • Regeneron (NASDAQ:REGN) stock rose 1.9% after the drugmaker announced that the U.S. government would buy an additional 1.4 million doses of its Covid-19 antibody treatment.

  • Sage Therapeutic (NASDAQ:SAGE) stock rose 3.4%, boosted by the FDA granting fast-track status to the drugmaker’s experimental treatment for Huntington’s disease. 

  • Citrix Systems (NASDAQ:CTXS) stock rose 5.8% after Bloomberg reported the software company is working with advisers to consider a possible sale. Activist investor Elliott recently disclosed at 10% stake in the company.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.